Rani Therapeutics Holdings, Inc. RANI
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Rani Therapeutics Holdings, Inc. (RANI) is a healthcare company listed in the US with a market value of about $61M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$32M, a net margin of -493.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 29% a year, a 5-year average ROIC of -105%.
About Rani Therapeutics
Rani Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $462000 in 2020 to $2M in 2025, growth of about 28.7% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 178% over three years (dilution for shareholders). It spends 1237% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $7M | $2M | $1M | $0 | $0 | $3M | $462000 |
| Net income | -$32M | -$30M | -$30M | -$34M | -$31M | -$8M | -$17M |
| Free cash flow | -$23M | -$19M | -$36M | -$52M | -$48M | -$33M | -$16M |
| EPS (diluted) | $-0.07 | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 | — |
| Net margin | -493.0% | -1817.1% | -2920.0% | — | — | -306.6% | -3615.4% |
| ROIC | — | -81.1% | -131.3% | -151.7% | -73.8% | -86.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $7.20, 1268% above the current price; targets range from $5.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.17 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Rani Therapeutics pay a dividend?
Not currently.
Is Rani Therapeutics a good stock to buy?
We do not give buy or sell advice. Rani Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.